Voyager Therapeutics (VYGR) Stock Forecast & Price Target

Compare

1,175 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VYGR Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Voyager

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VYGR Stock 12 Month Forecast

Average Price Target

$16.38

▲(378.95% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $16.38 with a high forecast of $30.00 and a low forecast of $8.00. The average price target represents a 378.95% change from the last price of $3.42.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.96,5.04,7.12,9.2,11.280000000000001,13.36,15.440000000000001,17.52,19.6,21.68,23.76,25.840000000000003,27.92,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.96,3.9923076923076923,5.024615384615384,6.056923076923076,7.089230769230769,8.12153846153846,9.153846153846153,10.186153846153845,11.218461538461536,12.25076923076923,13.283076923076923,14.315384615384612,15.347692307692306,{"y":16.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.96,3.3476923076923075,3.735384615384615,4.123076923076923,4.510769230769231,4.898461538461538,5.286153846153846,5.673846153846154,6.061538461538461,6.449230769230769,6.836923076923076,7.224615384615384,7.612307692307692,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.68,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.56,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.93,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$16.38

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dex Genotek

TR | OpenAI - 4o

$3.5

Hold

2.34%

Upside

Reiterated

08/27/25

AI Generated ArticleAI Generated Article

Sumant Kulkarni

Canaccord Genuity

$12

Buy

250.88%

Upside

Reiterated

08/14/25

Voyager Therapeutics: Strategic Positioning and Promising Pipeline Drive Buy RatingWe hosted a fireside chat with VYGR's CMO Toby Ferguson, CFO at our 2025 Boston, MA. Recall VYGR now has four wholly- owned Alzheimer's disease (AD) programs, i.e., VY7523 (anti-tau antibody), VY1706 (tau silencing gene therapy), a vectorized anti-amyloid beta antibody gene therapy, and a recently-announced bifunctional APOE4/2 gene therapy. The company's gene therapy programs utilize its proprietary TRACER capsid technology, which has shown promise in that it has been the subject of several external partnerships (e.g., Novartis, Neurocrine, etc.) that we view as providing some early external validation.

Patrick Trucchio

H.C. Wainwright

$30

Buy

777.19%

Upside

Reiterated

08/11/25

H.C. Wainwright Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)With $262 million in cash and a runway extended into 2028, we reiterate our Buy rating and $30 price target

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/08/25

Truist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

Debjit Chattopadhyay

Guggenheim

$22

Buy

543.27%

Upside

Reiterated

08/07/25

Pipeline updates and extended cash runway bolster our Buy rating with a $22 price target.

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/07/25

Voyager Therapeutics: Strong Financial Position and Promising Pipeline Drive Buy Rating

Jay Olson

Oppenheimer

$18

Buy

426.32%

Upside

Reiterated

08/07/25

Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer

Yun Zhong

Wedbush

Buy

133.92%

Upside

Reiterated

08/07/25

Analysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), Voyager Therapeutics (VYGR)

Lili (Aurélie) Nsongo

Leerink Partners

$12

Buy

250.88%

Upside

Reiterated

08/06/25

Voyager Therapeutics: Strategic Restructuring and Pipeline Progress Underpin Buy Rating

Jack Allen

Robert W. Baird

$18

Buy

426.32%

Upside

Reiterated

07/17/25

Voyager Therapeutics (VYGR) Gets a Buy from Robert W. Baird

Samantha Semenkow

Citi

$11

Buy

221.64%

Upside

Reiterated

07/16/25

Buy Rating for Voyager Therapeutics Driven by Promising Alzheimer's Gene Therapy and Significant Share Price Potential

Yanan Zhu

Wells Fargo

$10

Buy

192.40%

Upside

Reiterated

05/06/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Omnicell (NASDAQ: OMCL), Voyager Therapeutics (NASDAQ: VYGR) and Masimo (NASDAQ: MASI)

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Initiated

01/10/25

Cantor Fitzgerald starts Voyager Therapeutics (VYGR) at OverweightCantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Overweight rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dex Genotek

TR | OpenAI - 4o

$3.5

Hold

2.34%

Upside

Reiterated

08/27/25

AI Generated ArticleAI Generated Article

Sumant Kulkarni

Canaccord Genuity

$12

Buy

250.88%

Upside

Reiterated

08/14/25

Patrick Trucchio

H.C. Wainwright

$30

Buy

777.19%

Upside

Reiterated

08/11/25

H.C. Wainwright Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)With $262 million in cash and a runway extended into 2028, we reiterate our Buy rating and $30 price target

Joon Lee

Truist Financial

―

Buy

―

Reiterated

08/08/25

Truist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

Debjit Chattopadhyay

Guggenheim

$22

Buy

543.27%

Upside

Reiterated

08/07/25

Pipeline updates and extended cash runway bolster our Buy rating with a $22 price target.

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/07/25

Voyager Therapeutics: Strong Financial Position and Promising Pipeline Drive Buy Rating

Jay Olson

Oppenheimer

$18

Buy

426.32%

Upside

Reiterated

08/07/25

Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer

Yun Zhong

Wedbush

Buy

133.92%

Upside

Reiterated

08/07/25

Analysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), Voyager Therapeutics (VYGR)

Lili (Aurélie) Nsongo

Leerink Partners

$12

Buy

250.88%

Upside

Reiterated

08/06/25

Voyager Therapeutics: Strategic Restructuring and Pipeline Progress Underpin Buy Rating

Jack Allen

Robert W. Baird

$18

Buy

426.32%

Upside

Reiterated

07/17/25

Voyager Therapeutics (VYGR) Gets a Buy from Robert W. Baird

Samantha Semenkow

Citi

$11

Buy

221.64%

Upside

Reiterated

07/16/25

Buy Rating for Voyager Therapeutics Driven by Promising Alzheimer's Gene Therapy and Significant Share Price Potential

Yanan Zhu

Wells Fargo

$10

Buy

192.40%

Upside

Reiterated

05/06/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Omnicell (NASDAQ: OMCL), Voyager Therapeutics (NASDAQ: VYGR) and Masimo (NASDAQ: MASI)

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Initiated

01/10/25

Cantor Fitzgerald starts Voyager Therapeutics (VYGR) at OverweightCantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Voyager Therapeutics (NASDAQ: VYGR) with a Overweight rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Voyager Therapeutics

1 Month

xxx

Success Rate

8/12 ratings generated profit

Average Return

+3.29%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +3.29% per trade.

3 Months

xxx

Success Rate

8/18 ratings generated profit

Average Return

+4.27%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +4.27% per trade.

1 Year

Jack AllenRobert W. Baird

Success Rate

11/22 ratings generated profit

Average Return

-5.18%

reiterated a buy rating last month

Copying Jack Allen's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -5.18% per trade.

2 Years

xxx

Success Rate

9/22 ratings generated profit

Average Return

-19.68%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.91% of your transactions generating a profit, with an average return of -19.68% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VYGR Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VYGR has received 13 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. VYGR average Analyst price target in the past 3 months is 16.38.

Each month's total comprises the sum of three months' worth of ratings.

VYGR Financial Forecast

VYGR Earnings Forecast

Next quarter’s earnings estimate for VYGR is -$0.52 with a range of -$0.60 to -$0.32. The previous quarter’s EPS was -$0.57. VYGR beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.17% of the time in the same period. In the last calendar year VYGR has Outperformed its overall industry.

VYGR Sales Forecast

Next quarter’s sales forecast for VYGR is $7.86M with a range of $5.00M to $12.50M. The previous quarter’s sales results were $5.20M. VYGR beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year VYGR has Outperformed its overall industry.

VYGR Stock Forecast FAQ

What is VYGR’s average 12-month price target, according to analysts?

Based on analyst ratings, Voyager Therapeutics’s 12-month average price target is 16.38.

What is VYGR’s upside potential, based on the analysts’ average price target?

Voyager Therapeutics has 378.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VYGR a Buy, Sell or Hold?

Voyager Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Voyager Therapeutics’s price target?

The average price target for Voyager Therapeutics is 16.38. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $8.00. The average price target represents 378.95% Increase from the current price of $3.42.

What do analysts say about Voyager Therapeutics?

Voyager Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of VYGR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Voyager Therapeutics (VYGR) Stock Forecast & Price Target

VYGR Analyst Ratings

VYGR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Voyager Therapeutics

VYGR Analyst Recommendation Trends

VYGR Financial Forecast

VYGR Earnings Forecast

VYGR Sales Forecast

VYGR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts